New Zealand ニュージーランド Vol.9(economy, government, election, universities, corporations, etc. 経済、政府、選挙、大学、企業など)

All the below links and tweets are in English.

取り急ぎ標記につき以下貼っておきます。

New Zealand Vol.21 (corporations)
New Zealand Vol.20 (corporations)
New Zealand Vol.18 (organisations, government, etc.)
New Zealand Vol.6 (economy, industries)
New Zealand Vol.19 (University of Otago, Auckland University of Technology, Victoria University of Wellington)
New Zealand Vol.17 (University of Auckland, banks)
New Zealand Vol.16 (including University of Canterbury, University of Waikato, Lincoln University, Massey University)
New Zealand Vol.5 (Manifesto 2014 of NZ Labour Party – current largest opposition party; ruling party 1999-2008, et al.)
New Zealand Vol.4 (Manifesto 2014 of New Zealand National Party)
New Zealand Vol.1
cf.
New Zealand ニュージーランド Vol.5(#JacindaArdern coalition between Labour and New Zealand First アーダーン連立政権)
Crisis Management 危機管理 Vol.2
姉妹都市 Vol.3(Tripartite Economic Alliance ロサンゼルスLA=オークランドAK=広州GZ 三市経済連携)
New Zealand Vol.15 / Trans-Pacific Partnership #TPP Vol.1

ツイッター検索において「New Zealand Japan」等と入れて出て来たもの
@ANZCCJ

New Zealand ニュージーランド Vol.8(North Island 北島)

All the below links and tweets are in English.

取り急ぎ標記につき以下貼っておきます。リンクの日付が若干古いですが、最近アップデートしたものです。
All the below four were recently updated, though the dates are a little older.
New Zealand Vol.11 (Hawke’s Bay, Gisborne, Bay of Plenty)
New Zealand Vol.10 (Wellington, Manawatu-Whanganui)
New Zealand Vol.3 (Waikato, Taranaki)
New Zealand Vol.2 (Northland, Auckland)

英語ツイッター検索において日本及びニュージーランド北島関連で出て来たもの

New Zealand ニュージーランド Vol.7(North Island 北島)

All the below tweets are in Japanese.

取り急ぎ標記につき以下貼っておきます。

日本語ツイッター検索においてニュージーランド北島関連で出て来たもの(英語ツイート等は Vol.8 で。)

New Zealand ニュージーランド Vol.6(South Island 南島)

All the below links and about half of the below tweets are in English, and the rest of the below tweets are in Japanese.

取り急ぎ標記につき以下貼っておきます。リンクの日付が若干古いですが、最近アップデートしたものです。

All the below three were recently updated, though the dates are a little older.
New Zealand Vol.9 (Marlborough, Nelson&Tasman)
New Zealand Vol.8 (West Coast, Canterbury)
New Zealand Vol.7 (Southland, Otago)

ツイッター検索においてニュージーランド南島関連で出て来たもの

Austria オーストリア

All the below links and half of the below tweets are in English, and the other half are in Japanese.

取り急ぎ標記につき以下貼っておきます。

Austria Vol.3 (universities, etc.)
Austria Vol.2 (Legislative Election & Coalition 2017)
Austria Vol.1 (Miscellaneous incl Presidential Election 2016)

ツイッター検索においてオーストリア関連等で出て来たもの

Switzerland スイス

All the below links are in English, and most of the below tweets are in Japanese.

取り急ぎ標記につき以下貼っておきます。

Switzerland Vol.4 (University of St. Gallen, etc.)
Switzerland Vol.3
Switzerland Vol.2
Switzerland Vol.1

ツイッター検索でスイス関連で出て来たもの 


https://twitter.com/VogueChange/status/1258155848788033543


@swissinfo_jp
@SCCIJ

U.S.A. アメリカ Vol.105(Hawaii ハワイ州)

All the below links are in English, and most of the below tweets are in Japanese.

取り急ぎ標記につき以下貼っておきます。
Hawaii Vol.6
Hawaii Vol.5
Hawaii Vol.4 (corporations)
Hawaii Vol.3
Hawaii Vol.2
Hawaii Vol.1 

ツイッター検索でハワイ関連地名等を入れると出て来たもの

#Coronavirus #コロナウイルス Vol.5 / Science and Technology 科学技術 Vol.5(Pharmaceutical products 医薬品 Vol.1:Drugs & Vaccines 治療薬及びワクチン)

ご参考まで標記関連記事及び一部抜粋を以下貼っておきます。

Reasons for hope: The drugs, tests and tactics that may conquer coronavirus(04/17/2020) | Christine Soares @reuters,@stltoday

DRUGS
Remdesivir (Gilead Sciences)
Antiviral drug, originally developed to combat RNA viruses including respiratory syncytial virus. …antivirals work best when patients are healthier…
Hydroxychloroquine and chloroquine
Malaria drug also believed to have antiviral activity. Blocked SARS-CoV-2 entry into cells in an in-vitro experiment. …
Actemra or tocilizumab (Roche)
Monoclonal antibody approved for rheumatoid arthritis and also for treating the “cytokine storm” immune overresponse in cancer patients. …
Kevzara or sarilumab (Sanofi, Regeneron Pharmaceuticals)
Monoclonal antibody approved for inflammatory arthritis, and in trials targeting the “cytokine storm” immune response in severely ill COVID-19 patients. …
Jakavi or ruxolitinib (Novartis, Incyte)
Developed to treat inflammatory and autoimmune diseases, and in late-stage development as a cream for atopic dermatitis. …
Kaletra or lopinavir-ritonavir (Abbvie)
Antiviral combination used to treat and prevent HIV infections. …
(rhACE2) APN01 (Apeiron Biologics)
A recombinant human angiotensin converting enzyme 2 (rhACE2) under Phase-2 clinical development in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension). …
Camostat Mesylate (University of Aarhus, Denmark)
Protease inhibitor licensed in Japan and South Korea to treat chronic pancreatitis. In vitro experiments found it blocks a mechanism SARS-Cov-2 uses to enter human cells. … The University of Tokyo also announced plans for a trial of camostat mesylate and a related drug, nafamostat mesylate, starting as early as April 2020.
IFX-1 (InflaRx)
Monoclonal antibody targeting complement activation product C5a. Designed to block a mechanism of inflammation…
Aspirin, clopidogrel, rivaroxaban, atorvastatin, omeprazole (Imperial College, London)
Trial of cardioprotective drugs to prevent direct damage to the heart muscle that appears to drive the severity of COVID-19…

VACCINES
MRNA 1273 (Moderna/NIAID)
RNA vaccine made with messenger-RNA (mRNA) encoding the spike protein of SARS-CoV-2 encapsulated in a lipid nanoparticle. …
NVX-COV2373 (Novavax)
…enhance immune responses. …
Lentiviral minigene vaccines (LV-SMENP) (Shenzhen Geno-Immune Medical Institute)
Engineered minigenes encoding viral antigens; lentiviral vector designed to infect dendritic and T cells to induce immunity. …
BCG tuberculosis vaccine (Murdoch Children’s Research Institute; UMC Utrecht)
Bacillus Calmette-Guérin tuberculosis vaccine that induces a broad innate immune-system response, which has been shown to protect against infection or severe illness with other respiratory pathogens. …
INO-4800 (Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations)
DNA plasmid vaccine delivered into the skin via a patch-style electroporation device. …
AD5-NCOV (Cansino Biological Inc. / Beijing Institute of Biotechnology)
Non-replicating viral vector. …
CHADOX1 (University of Oxford)
Non-replicating chimpanzee adenovirus vector. …

Science and Technology 科学技術 Vol.4(Telemedicine 遠隔医療 Vol.1)/ #Coronavirus #コロナウイルス Vol.4

標記につきアメリカの現状が少し分かる最近の記事2本とその抜粋を、以下貼っておきます。

In the time of coronavirus, telemedicine brings physicians where they’re needed most – Expert Opinion (04/10/2020) | Frederick Hitti @PhillyInquirer
… The system’s most obvious use is permitting physicians who are unable to physically come to the hospital – perhaps because they are under quarantine – to remotely care for patients. This telemedicine system is also a boon for physicians physically present at the hospital. There is a severe shortage of personal protective equipment (PPE) such as gowns and masks, so the eICU system could be used to care for patients without entering the room, reducing the amount of PPE used. Furthermore, the computer system monitors vital signs and alerts physicians if a patient’s condition deteriorates. The eICU system and other telemedicine systems are also enabling critical care and emergency department doctors to remotely consult doctors in other specialties, providing the best multidisciplinary care. …

A healthy connection: Pandemic shows need for rural broadband as health care providers turn to telemedicine (04/18/2020) | Anna Brugmann @columbiatribune
… Yet, some practitioners and patients have been slow to incorporating telehealth into their daily practice. Not only can it be an additional time tax on busy rural providers, but some patients find it strange to discuss something as intimate as health outcomes from their sofa. …
…86% of Missourians have access to internet speeds of 25 megabits a second (mbps)…
Standard internet video services, like Zoom, require speeds of 0.6 and 1.2 mbps for an extended period of time. But the higher the internet speeds, the more people and devices can operate on one line. All of this makes fiber internet ideal for video conferencing and household use. …

#Coronavirus #コロナウイルス Vol.3 / Science and Technology 科学技術 Vol.3

What does 5G have to do with coronavirus? Where did it come from? Your questions answered (09/04/2020) | @DWNews

コロナウイルス関連説明が分かり易いので、下記抜粋をご紹介します。

Where did SARS-CoV-2 come from?
Scientific consensus agrees that the novel coronavirus is natural — it’s a zoonotic disease, meaning it was transmitted from animals to humans. It’s widely thought that the virus originated in bats, before possibly passing through another mammal that infected a human.
In early February, Nature published a study showing that the novel coronavirus is 96% identical at the whole-genome level to a bat coronavirus.
Another study found that pangolins — a scaly anteater that is heavily trafficked in parts of Asia and Africa — carry coronaviruses that are very similar to SARS-CoV-2. …

Will I die of COVID-19?
This question can’t be answered with a simple “yes” or “no,” just like death from the flu or a car accident can’t be predicted with certainty. We can only speak of probabilities. And even that is not so easy in the case of COVID-19, which is why we have prepared a detailed breakdown of the statistics here …
… the virus’ casualty rate is between 0.5 to 2%, i.e. one or two people die out of every 100 people who are infected.

How long can the virus survive in the air or on surfaces?
… But the good news is that the virus needs a live host to survive. Without a live host, the virus eventually dies out because it can’t copy itself. So while it may survive on some surfaces for hours and even days, over time it becomes less infectious because, without being able to replicate, the virus breaks down over time.
… temperature changes and sunlight — that could affect the stability of the virus.

Why isn’t there a vaccine yet?
It normally takes years to develop an effective and safe vaccine.
… there are at least 47 ongoing projects globally focussing on the development of a coronavirus vaccine. …
… Scientists at the DZIF use pre-existing “building blocks” from previously formulated vaccines to work towards the development of a coronavirus vaccine. Although the scientists are working under high pressure, it’s not possible for a vaccine to be launched on the market this year. The clinical studies, which are crucial for approval, take time.
Parallel to the development of the vaccine, some researchers are working on developing a “passive immunization” with antibodies derived from blood serum. These come from people who have survived a SARS-CoV-2 infection and therefore have antibodies in their blood that can fight the virus.
It’s called passive immunization, because the recipient body hasn’t actively produced any antibodies itself. And as a result, the antibodies it “borrows” will provide protection or help to fight an infection, but only for a short period of time. Only a traditional vaccine will provide long term protection from coronavirus. …